Browsing by Author "Soza, Alejandro"

Now showing 1 - 20 of 52
  • Thumbnail Image
    Item
    A changing etiologic scenario in liver transplantation for hepatocellular carcinoma in a multicenter cohort study from Latin America
    (2018) Piñero, Federico; Costa, Paulo; Boteon, Yuri Longatto; Hoyos Duque, Sergio; Marciano, Sebastian; Anders, Margarita; Varon, Adriana; Zerega, Alina; Poniachik, Jaime; Soza, Alejandro; Padilla Machaca, Martin; Menendez, Josemaria; Zapata, Rodrigo; Vilatoba, Mario; Munoz, Linda; Maraschio, Martin; Podesta, Luis G.; McCormack, Lucas; Gadano, Adrian; Fatima Boin, Ilka S. F.; Garcia, Parente; Silva, Marcelo
  • Thumbnail Image
    Item
    An update on the management of hepatitis C : guidelines for protease inhibitor-based triple therapy from the Latin American Association for the Study of the Liver
    (2013) Chávez Tapia, Norberto C.; Ridruejo, Ezequiel; Alves De Mattos, Angelo; Bessone, Fernando; Druich, Jorge; Sánchez Avila, Juan F.; Cheinquer, Hugo; Zapata, Rodrigo; Uribe, Misael; Soza, Alejandro; Bosques Padilla, Francisco; Gadano Espinoza, Adrián; Dávalos Moscol, Milagro; Marroni, Claudio; Muñoz Espinoza, Linda; Castro Narro, Graciela; Paraná, Raimundo; Méndez Sánchez, Nahum
  • Thumbnail Image
    Item
    Analysis of natural variants of the hepatitis C virus internal ribosome entry site reveals that primary sequence plays a key role in cap-independent translation
    (OXFORD UNIV PRESS, 2009) Ines Barria, Maria; Gonzalez, Angel; Vera Otarola, Jorge; Leon, Ursula; Vollrath, Valeska; Marsac, Delphine; Monasterio, Octavio; Perez Acle, Tomas; Soza, Alejandro; Lopez Lastra, Marcelo
    The HCV internal ribosome entry site (IRES) spans a region of similar to 340 nt that encompasses most of the 5' untranslated region (5'UTR) of the viral mRNA and the first 24-40 nt of the core-coding region. To investigate the implication of altering the primary sequence of the 5'UTR on IRES activity, naturally occurring variants of the 5'UTR were isolated from clinical samples and analyzed. The impact of the identified mutations on translation was evaluated in the context of RLuc/FLuc bicistronic RNAs. Results show that depending on their location within the RNA structure, these naturally occurring mutations cause a range of effects on IRES activity. However, mutations within subdomain IIId hinder HCV IRES-mediated translation. In an attempt to explain these data, the dynamic behavior of the subdomain IIId was analyzed by means of molecular dynamics (MD) simulations. Despite the loss of function, MD simulations predicted that mutant G266A/G268U possesses a structure similar to the wt-RNA. This prediction was validated by analyzing the secondary structure of the isolated IIId RNAs by circular dichroism spectroscopy in the presence or absence of Mg2+ ions. These data strongly suggest that the primary sequence of subdomain IIId plays a key role in HCV IRES-mediated translation.
  • No Thumbnail Available
    Item
    Baveno VI and Expanded Baveno VI criteria successfully predicts the absence of high-risk gastro-oesophageal varices in a Chilean cohort
    (2020) Gaete Celis, María Isabel; Díaz Piga, Luis Antonio; Arenas Fajardo, Cristian Alexis; Gonzalez, K.; Cattaneo, M.; Soza, Alejandro; Arrese, Marco; Barrera Martínez, Francisco José; Arab Verdugo, Juan Pablo; Benítez, Carlos; Fuster, F.; Henriquez, R.
  • Thumbnail Image
    Item
    Conversion to mycophenolate mofetil monotherapy in liver recipients: Calcineurin inhibitor levels are key
    (2017) Norero, Blanca; Serrano Honeyman, Carolina; Sánchez Fueyo, A.; Duarte, Ignacio; Torres Montes, Paula Javiera; Ocqueteau Tachini, Mauricio; Barrera Martínez, Francisco José; Arrese Jiménez, Marco; Soza, Alejandro; Benítez, Carlos
  • Thumbnail Image
    Item
  • Thumbnail Image
    Item
    Decompensated cirrhosis and liver transplantation negatively impact in DAA treatment response: Real-world experience from HCV-LALREAN cohort
    (2020) Ridruejo, Ezequiel; Piñero, Federico; Mendizabal, Manuel; Cheinquer, Hugo; Soza, Alejandro; Herz Wolff, Fernando; Anders, Margarita; Reggiardo, Virginia; Ameigeiras, Beatriz; Palazzo, Ana; Alonso, Cristina; Schinoni, María Isabel; Videla Zuain, María Grazia; Tanno, Federico; Figueroa, Sebastián; Santos, Luisa; Peralta, Mirta; Vistarini, Cecilia; Adrover, Raúl; Fernández, Nora
  • Thumbnail Image
    Item
    Detection of high biliary and fecal viral loads in patients with chronic hepatitis C virus infection
    (2017) Monrroy Bravo, Hugo Alfonso; Angulo, J.; Pino, Karla; Labbé, P.; Miquel P., Juan Francisco; López Lastra, Marcelo Andrés; Soza, Alejandro
  • Thumbnail Image
    Item
    Disease Progression in Patients With Hepatitis C Virus Infection Treated With Direct-Acting Antiviral Agents
    (2020) Mendizabal, M.; Piñero, F.; Ridruejo, E.; Herz Wolff, F.; Anders, M.; Reggiardo, V.; Ameigeiras, B.; Palazzo, A.; Alonso, C.; Soza, Alejandro; Schinoni, M. I.; Videla Zuain, M. G.; Tanno, F.; Figueroa, S.; Santos, L.; Peralta, M.; Vistarini, C.; Adrover, R.; Fernández, N.; Pérez, D.; Hernández, N.; Estepo, C.; Bruno, A.; Descalzi, V.; Sixto, M.; Borzi, S.; Cocozzella, D.; Zerega, A.; de Araujo, A.; Varón, A.; Rubinstein, F.; Cheinquer, H.; Silva, M.
  • Thumbnail Image
    Item
    Effect of ezetimibe in HCV viral load after liver transplantation
    (2016) Monrroy Bravo, Hugo Alfonso; Angulo, J.; Pino, Karla; Labbé, P.; López Lastra, Marcelo Andrés; Soza, Alejandro
  • Thumbnail Image
    Item
    Effectiveness of the implementation of a re-linkage to care strategy in patients with Hepatitis C who were lost of follow-up
    (2021) Mendizabal, Manuel; Thompson, Marcos Andres; Ridruejo, Ezequiel; Gonzalez Ballerga, Esteban; Ruiz Velasco, Jose Antonio Velarde; Palazzo, Ana; Mezzano, Gabriel; Muñoz Espinosa, Linda Elsa; Pessoa, Mario; Cerda Reyes, Eira; Soza, Alejandro; Ruiz, Sandro; Gomez-Aldana, Andres Jose; Gerona, Solange; Fuster, Francisco; Anders, Margarita; Beltran Valdivia, Flor De Maria; Poniachik, Jaime; Schinoni, Maria Isabel; Hernandez, Nelia; Montes, Pedro; Girala, Marcos; Castillo, Lida; Castillo-Barradas, Mauricio; Chavez, Rocio; Cabrera, Cecilia; Tenorio, Laura; Zevallos, Katherine; Garavito, Jorge; Brutti, Julia; Tagle, Martin; Castro Narro, Graciela; Vera Pozo, Emilia; Perazzo, Rosalia; Guillermo Toro, Luis; Varon, Adriana; Ferreiro, Melina; Lazcano, Monserrat; Dolores Murga, Maria; Gomez, Fernando; Hernandez, Larissa; Damasio Moutinho, Bruna; Gandara-Calderon, Julian; Vargas Domínguez, José Ignacio; Simian, Daniela; Silva, Marcelo
    Background: In order to achieve the World Health Organization’s ambitious goal of eliminating hepatitis C (HCV), we must implement innovative strategies to diagnose and treat more patients. Therefore, our study aimed to identify patients with chronic HCV infection who lost follow-up and offer them re-linkage to care and treatment with direct-acting antivirals (DAAs). Methods: We conducted an implementation study of a strategy to contact patients with chronic HCV who were not under regular follow-up in 10 countries from Latin America. Patients with HCV were identified by the international classification of diseases (ICD-9/10) or similar. Medical records were then reviewed to confirm the diagnosis of chronic HCV infection defined as anti-HCV + and detectable HCVRNA. Identified patients who were not under follow-up by a liver specialist were contacted to offer them a medical reevaluation and, eventually, treatment with DAA. Results: A total of 3,709 patients were classified as HCV, of which 367 (9.9%) presented undetectable HCVRNA, and 148 (4.0%) were wrongly coded. Overall, 3,194 (86.1%) individuals were identified with chronic HCV infection, 49,9% were male, median age was 61 years (IQR 51-69); 166 (5.2%) developed hepatocellular carcinoma, and 117 (3.7%) underwent liver transplantation. Advanced liver fibrosis (F3-F4) was present in 1,361 (42.6%) patients. A total of 1,764 (55.2%) patients were under close care. Of these, 1,371 (74.7%) received antiviral treatment, 70 (5.3%) did not achieve sustained virologic response, 314 (17.8%) were not treated for different reasons and 133 (7.5%) died. We identified 1,430 (44.8%) patients who were lost of follow-up, 564 (39.4%) of whom were finally located. Of those contacted, 402 (71.3%) were candidates to receive DAAs, 108 (19.2%) were treated in other institutions, 12 (2.1%) did not wish to be treated, and 42 (7.4%) died (Figure). Globally, in our study 786/3,194 (24.6%) patients were candidates to receive antiviral therapies. Conclusion: In our cohort, 1 out of 4 patients with chronic HCV could be re-linked to care and treated. This strategy impresses to be effective, accessible and, significantly impact on the HCV cascade to cure.
  • Thumbnail Image
    Item
    Efficacy and safety of ombitasvir/paritaprevir/r and dasabuvir compared to IFN-containing regimens in genotype 1 HCV. patients: The MALACHITE-I/II. trials.
    (2016) Dore, G. J.; Conway, B.; Luo, Y.; Janczewska, E.; Knysz, B.; Liu, Y.; Streinu-Cercel, A.; Caruntu, F. A.; Curescu, M.; Soza, Alejandro
  • Thumbnail Image
    Item
    Estudio de impacto presupuestal de Daclatasvir asociado a Asunaprevir desde la perspectiva del sistema de salud público chileno
    (2017) Vargas, C.; Espinoza Sepúlveda, Manuel Antonio; Giglio, A.; Soza, Alejandro
  • Thumbnail Image
    Item
  • Thumbnail Image
    Item
    Evaluación de docentes clínicos de Postgrado: desarrollo y propiedades psicométricas del instrumento MEDUC-PG14
    (2015) Pizarro Rojas, Margarita Alicia; Solís, Nancy; Rojas, Viviana; Díaz, Luis Antonio; Padilla, Oslando; Letelier Saavedra, Luz María; Aizman, Andrés; Sarfatis Feige, Alberto; Olivos, Trinidad; Soza, Alejandro; Delfino, Alejandro; Latorre, Gonzalo; Ivanovic-Zuvic, Danisa; Hoyl, Trinidad; Bitrán Carreño, Marcela; Arab Verdugo, Juan Pablo; Riquelme Pérez, Arnoldo; Pizarro, Margarita; Solís, Nancy; Rojas, Viviana; Díaz, Luis Antonio; Padilla, Oslando; Letelier Saavedra, Luz María; Aizman, Andrés; Sarfatis Feige, Alberto; Olivos, Trinidad; Soza, Alejandro; Delfino, Alejandro; Latorre, Gonzalo; Ivanovic-Zuvic, Danisa; Hoyl, Trinidad; Bitrán Carreño, Marcela; Arab Verdugo, Juan Pablo; Riquelme Pérez, Arnoldo
  • Thumbnail Image
    Item
    Fragmento sérico de citoqueratina-18 como marcador no invasivo de esteatohepatitis no alcohólica en población chilena
    (2017) Arab Verdugo, Juan Pablo; Hernández Rocha, Cristián Antonio; Morales, Carolina; Vargas Domínguez, José Ignacio; Solis, Nancy; Pizarro Rojas, Margarita Alicia; Robles, Camila; Sandoval, Daniela; Ponthus, Simon; Benítez Gajardo, Carlos Esteban; Barrera Martínez, Francisco José; Soza, Alejandro; Riquelme Pérez, Arnoldo; Arrese, Marco
    La esteatohepatitis no alcohólica (EHNA) es la forma más agresiva de hígado graso no alcohólico (HGNA) e involucra el riesgo de progresión a etapas más avanzadas de enfermedad hepática. Se requieren métodos no invasivos para identificar a pacientes con EHNA. Objetivo: Evaluar el rendimiento diagnóstico de la determinación de los niveles séricos de citoqueratina-18 como marcador no invasivo de EHNA en población chilena. Métodos: Se determinaron los niveles séricos de CK-18 en un grupo de 41 pacientes con HGNA-probado por biopsia. El diagnóstico de EHNA se basó en los criterios histológicos recomendados (presencia de balonamiento) y se calculó el puntaje de actividad del HGNA (PAH) y grado de fibrosis. Mediante correlación de Spearman se evaluó la asociación entre CK-18 y PAH. Se confeccionó una curva ROC para evaluar la capacidad de CK-18 como test diagnóstico para EHNA. Además, se evaluó el rendimiento del puntaje de fibrosis en hígado graso no alcohólico (NFS) para pesquisa de fibrosis y EHNA y se lo comparó con CK-18 por regresión lineal simple. Los datos son expresados en medianas [percentil 25-75] y evaluados con test de rangos de Wilcoxon. Resultados: La edad promedio del grupo estudiado (23% hombres) fue de 50,4±11,1 años. Un 34,2% fue diagnosticado con EHNA (PAH≥5). Los niveles de CK-18 fueron mayores en los pacientes con EHNA versus los sin EHNA (183,6 UI/l [97,4-734,4] vs. 117,2 UI/l [83,8-954,8], p=0,016). Los niveles de CK-18 fueron buenos predictores de la presencia de EHNA en la biopsia con un área bajo la curva (AUC) de 0,732 (IC95% 0,572-0,897). Un punto de corte de 130,5 UI/l de CK-18 exhibió una sensibilidad de 92,9% y una especificidad de 63%, con un VPP de 56,5% y un VPN 94,4%, y clasificó correctamente al 73,2% de los pacientes con EHNA. El NFS tuvo un buen rendimiento para diagnóstico de fibrosis avanzada (AUC 0,739, IC95% 0,56–0,91), pero limitado para identificar EHNA (AUC 0,413, IC95% 0,21-0,61). Conclusión: La determinación de CK-18 es un buen marcador no invasivo de EHNA. Si bien, NFS tiene un buen rendimiento en la identificación de pacientes con fibrosis avanzada, no fue de utilidad para diagnosticar EHNA. En pacientes con HGNA, la determinación de CK-18 y NFS es útil en la pesquisa de EHNA y fibrosis hepática respectivamente.
  • Thumbnail Image
    Item
    GALECTIN-8 Is a Neuroprotective Factor in the Brain that Can Be Neutralized by Human Autoantibodies
    (2019) Pardo Huguet, Evelyn Cristina; Barake Sabbagh, M. Francisca; Godoy Zeballos, Juan Alejandro; Oyanadel, C.; Espinoza, S.; Metz Baer, Claudia Andrea; Retamal, C.; Massardo Vega, Loreto; Tapia-Rojas, Cheril; Inestrosa Cantín, Nibaldo; Soza, Alejandro; Gonzalez, A.
  • Thumbnail Image
    Item
    Genetic variations in host IL28B links to the detection of peripheral blood mononuclear cells-associated hepatitis C virus RNA in chronically infected patients
    (2013) Angulo, Jenniffer; Pino, Karla; Pavez, C.; Biel, F.; Labbé, Pilar; Miquel P., Juan Francisco; Soza, Alejandro; López Lastra, Marcelo Andrés
  • Thumbnail Image
    Item
    Hepatitis C virus may have an entero-hepatic cycle which could be blocked with ezetimibe
    (2017) Monrroy Bravo, Hugo Alfonso; López Lastra, Marcelo Andrés; Soza, Alejandro
  • Thumbnail Image
    Item
    HIV Through the Looking Glass: Insights Derived From Hepatitis B
    (2015) Rivera, M.M.; Soza, Alejandro; Jazwinski, A.; Mi, L.J.; Kleiner, D.E.; Zhao, X.; Zuber, C.; Brust D.; Hsu, E.; Brust, D.; Simpson, J.; Hoofnagle, J.H.; Heller, T.